Abstract: A fluid sensing device includes an outer shell, a three-axis force and moment balance, a strut, and a centerbody. The outer shell has an inlet at a first end of the outer shell, an aft vent at an opposing second end of the outer shell, and an interior space connecting the inlet and the aft vent. The three-axis force and moment balance is positioned in the interior space of the outer shell. The strut is connected to the outer shell and the three-axis force and moment balance such that the strut supports the three-axis force and moment balance in the interior space. At least a portion of the centerbody is positioned in the interior space of the outer shell. The centerbody is connected to the three-axis force and moment balance such that the three-axis force and moment balance is configured to measure force, moment, and/or movement of the centerbody.

Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, oral mucositis, mucositis, and proctitis by the administration of a compound Yel002/BCN057 or an analog thereof.

Abstract: The present disclosure relates to tertiary amine co-initiators that demonstrate reduced leaching and which may be utilized in dental restoration and other biomedical applications. Embodiments of the present disclosure provide compounds and compositions for use in preparing polymers and light curable dental resin composites, as well as methods for preparing photocurable polymer-based dental restorative materials. In one or more disclosed embodiments, a co-initiator for use in preparing a polymer comprises a tertiary amine core and two or more pendant, terminal methacrylate groups. In some embodiments, the co-initiator may also act as a co-monomer in a co-polymerization reaction.

Abstract: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.

Abstract: Electrodes are provided comprising a FeS2 electrocatalytic material, the FeS2 electrocatalytic material comprising FeS2 nanostructures in the form of FeS2 wires, FeS2 discs, or both, wherein the FeS2 wires and the FeS2 discs are hyperthin having a thickness in the range of from about the thickness of a monolayer of FeS2 molecules to about 20 nm. The FeS2 nanostructures may be polycrystalline comprising a non-pyrite majority crystalline phase. The FeS2 nanostructures may be in the form of FeS2 discs wherein substantially all the FeS2 discs have at least partially curved edges.

Abstract: Compounds can be used for treating polycystic kidney disease (PKD). As such, these compounds can be used in associated methods. The methods can include: method of modulating (e.g., activating) Liver kinase B1 (LKB1); method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway.

Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.

Abstract: A microfluidic exosome profiling platform integrating exosome isolation and targeted proteomic analysis is disclosed. This platform is capable of quantitative exosomal biomarker profiling directly from 30 ?L plasma samples within approximately 100 minutes with markedly enhanced sensitivity and specificity. Identification of distinct subpopulation of patient-derived exosomes is demonstrated by probing surface proteins and multiparameter analyses of intravesicular biomarkers in the selected subpopulation. The expression of IGF-1R and its phosphorylation level in non-small cell lung cancer (NSCLC) patient plasma is assessed, as a non-invasive alternative to the conventional biopsy and immunohistochemistry.

Abstract: A system and method for evaluating wound healing dressings, treatments, and other variables. The present invention includes in vitro systems and methods for testing wound dressing materials for bacterial control, moisture control, and surface contact properties. The present invention further includes in vivo systems and methods for testing wound dressings, treatments, and other variables utilizing arrays of wound wells on an experimental subject animal. Wound arrays allow for different wound healing variables to be tested with numerous experimental trials within the same subject animal, giving reliable results and reducing the number of subject animals required for testing.

Abstract: Ratio of neutrophils to lymphocytes (NLR) is here associated with immune suppression and decreased survival times in multiple solid tumors. Based on immune cell-specific DMRs and validated cell deconvolution algorithms, the NLR in blood from glioma patients was estimated and glioma patients had elevated mdNLR scores compared to controls. The patient mdNLR scores were increased in patients with grade IV tumors compared to grade II/III. High mdNLR scores were associated with shorter survival. Candidate single (myeloid-associated) gene loci that were highly correlated with the mdNLR were identified. Single myeloid differentiation loci provide a simpler and cheaper alternative to the mdNLR, which requires complex array data. Immunomethylomics are useful and more convenient than conventional cell analysis in profiling glioma risk and survival.

Abstract: A barrier system is provided for use in reducing infections associated with post-operative surgical incision and/or a percutaneous medical device, such as a catheter, that is disposed within the surgical incision. Such a barrier system may include: a barrier device having a skin-contacting surface and a catheter-receiving surface; and an adhesive composition configured for adhering to skin, the barrier device, and/or the catheter so as to form a barrier at or adjacent to an incision in the skin where the catheter is percutaneously inserted through the skin. A tensioning anchor and associated system of two or more tensioning anchors is provided for post-operative wound closure. A method for applying and removing the barrier device and tensioning anchors is also provided.

Abstract: The invention is directed to polymers that self-crosslink at acidic pH or can be crosslinked by phenolic agents in brine. Such polymers have lower viscosity and can be pumped deep into reservoirs, where they will cross link in situ, thus increasing their viscosity and/or form a gel and blocking thief zones. Methods of making and using such polymers are also provided.

Abstract: A compound can be a fluorescent taxane derivative having a structure of Formula 1, salt, stereoisomer, tautomer, polymorph, or solvate thereof. Formula 1 can be defined as: L, L-NH, or L-NH—C?O is a linker; and R is a substituent, where —OH, —O?, —NH2, and NH—CH3 are examples. Examples of linkers can include glycine, beta-alanine, gamma-aminobutyric acid (GABA). Pharmaceutical compositions can include the compound and a pharmaceutically acceptable carrier, and may be configured for intravenous injection. The fluorescent taxane derivative can be used to treat cancer and non-cancer diseases. The fluorescent taxane derivative can be used to monitor cellular efflux and determine whether a cell will efflux paclitaxel.

Abstract: A cannula device for draining sub-retinal fluid externally to the eye includes a shaft, an outer sleeve, and an inner sleeve. The outer sleeve and the inner sleeve have a curve therein to access the back of the eye externally. The outer sleeve is extendable relative to the inner sleeve and the shaft, and the outer sleeve includes a penetrative tip to penetrate the sclera and provide access to the sub-retinal fluid to the inner sleeve.

Abstract: A method for processing lignin may comprise flowing a lignin composition comprising a lignin polymer and a solvent through a reaction chamber of a continuous flow reactor, the lignin polymer comprising hydroxycinnamic groups bound to a polymeric backbone; flowing ozone through the reaction chamber containing the lignin composition under conditions to maximize oxidative cleavage of the hydroxycinnamic groups to produce one or more types of aromatic monomers while minimizing oxidative cleavage of the polymeric backbone; and collecting the one or more types of aromatic monomers, e.g., by a size-selective membrane separation device.

Abstract: The description relates to a method and kits for determining the total carbonylation level on a polypeptide.

Abstract: The disclosure relates to nerve derived adult pluripotent stem cells characterized by expression of Oct4, Sox2, c-Myc, and Klf4, methods for obtaining them, and their use.

Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.

Abstract: A microfluidic exosome profiling platform integrating exosome isolation and targeted proteomic analysis is disclosed. This platform is capable of quantitative exosomal biomarker profiling directly from plasma samples with markedly enhanced sensitivity and specificity. Identification of distinct subpopulation of patient-derived exosomes is demonstrated by probing surface proteins and multiparameter analyzes of intravesicular biomarkers in the selected subpopulation. The expression of IGF-1R and its phosphorylation level in non-small cell lung cancer (NSCLC) patient plasma is assessed as a non-invasive alternative to the conventional biopsy and immunohistochemistry. Detection of ovarian cancer also is assessed. The microfluidic chip, which may be fabricated of a glass substrate and a layer of poly(dimethylsiloxane), includes a serpentine microchannel to mix a fluid and a microchamber for the collection and detection of exosomes.